---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-108717"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2024-04-24T23:59:59+00:00"
generated_at: "2026-06-03T09:51:10.608607+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Centessa prices $100M ADS offering at $9.25; pro forma cash enables runway into mid-2026

## Summary
- Priced 10,810,810 ADSs at $9.25/ADS; gross proceeds ~$100M. Close expected Apr 26, 2024.
- Net proceeds estimated at $93.5M (or $107.6M if over-allotment exercised).
- Underwriters granted 30-day option to purchase up to 1,621,621 additional ADSs.
- Preliminary cash, equivalents & ST investments at Mar 31, 2024: $230.2M.
- Proceeds to fund product candidate development and general corporate purposes; runway extended into mid-2026.

## SEC filing metadata
- accession: 0001193125-24-108717
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2024-04-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000119312524108717/0001193125-24-108717-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000119312524108717/d740386d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-108717
- JSON: https://secwatch.observer/filing/0001193125-24-108717.json
- Plain text: https://secwatch.observer/filing/0001193125-24-108717.txt

## Key facts
- Material Agreements
  Centessa Pharmaceuticals plc entered into "Underwriting Agreement" with Goldman Sachs & Co. LLC and Leerink Partners LLC, as representatives of the underwriters named therein (effective 2024-04-23).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Goldman Sachs & Co. LLC and Leerink Partners LLC, as representatives of the underwriters named therein
  - Effective: 2024-04-23
  source text: On April 23, 2024, Centessa Pharmaceuticals plc (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC and Leerink Partners LLC, as representatives (the “Representatives”) of the underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 10,810,810 American Depositary Shares (the “ADSs”), each presenting one ordinary share, with a nominal value £0.002 per share (the “Ordinary Share”), of the Company (the “Firm ADSs”), at a price to the public of $9.25 per ADS (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847903/000119312524108717/0001193125-24-108717-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.